AstraZeneca plc  

(Public, LON:AZN)   Watch this stock  
Find more results for AZN
4,989.50
-90.50 (-1.78%)
Real-time:   1:20PM GMT+1
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,926.95 - 5,079.18
52 week 3,680.00 - 5,505.00
Open 5,024.00
Vol / Avg. 1.02M/2.84M
Mkt cap 62.92B*
P/E 37.60
Div/yield 68.70*
EPS 1.33*
Shares 1.26B
Beta     -
Inst. own     -
*GBP
Nov 10, 2016
Q3 2016 AstraZeneca PLC Earnings Release - 7:00AM GMT - Add to calendar
Sep 22, 2016
AstraZeneca PLC Investor Roadshow - Dublin Add to calendar
Sep 22, 2016
AstraZeneca PLC Investor Roadshow - Helsinki Add to calendar
Sep 14, 2016
AstraZeneca PLC at Bank of America Merrill Lynch Healthcare Conference Add to calendar
Sep 13, 2016
AstraZeneca PLC Investor Roadshow - Copenhagen Add to calendar
Sep 12, 2016
AstraZeneca PLC at Morgan Stanley Global Healthcare Conference Add to calendar
Sep 8, 2016
AstraZeneca PLC Investor Roadshow - Benelux Add to calendar
Sep 7, 2016
AstraZeneca PLC at Wells Fargo Securities Healthcare Conference Add to calendar
Aug 24, 2016
AstraZeneca PLC at CFA Society of Minnesota's InvestMNt Conference
Aug 24, 2016
AstraZeneca PLC Investor Roadshow - Mid West
  

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -0.55% 11.44%
Operating margin 5.41% 16.65%
EBITD margin - 33.23%
Return on average assets -0.19% 4.76%
Return on average equity -0.09% 14.82%
Employees 61,500 -
CDP Score - 97 B

Address

- Legal Department, 2 Kingdom Street
LONDON, W2 6BD
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 56
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 62
Fiona Cicconi Executive Vice-President, Human Resources
Sean Bohen M.D. Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Ruud Dobber Executive Vice President, Europe
Paul Hudson President, AstraZeneca, US and Executive Vice-President, North America
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Mark Mallon Executive Vice President, International
Luke Miels Executive Vice-President, GPPS
Menelas Pangalos Executive Vice President - Innovative Medicines